Beyond GLP-1 Drugs: This Opportunity at Eli Lilly Could Surprise Everyone in 2025
Mounjaro and Zepbound are Eli Lilly's largest sources of growth, but there is much more to the company.
Over the last couple of years, the pharmaceutical sector has captivated investors thanks in large part to novel medications used to treat chronic weight management and diabetes.
While you may be more familiar with brand names such as Ozempic or Wegovy, these drugs are known as glucagon-like peptide-1 (GLP-1) agonists in the medical world. Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of blockbuster treatments, Mounjaro and Zepbound.
While Lilly's success with GLP-1 drugs is certainly impressive, I have my eyes on another area of the company this year. Let's dig into what Lilly's business looks like beyond weight loss treatments, and explore which of the company's tailwinds has me most excited.
